A Case of Primary Malignant Melanoma of the Nasolacrimal Duct
Related Experiment Video
Updated: Jan 7, 2026

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Kosuke Terazawa1, Ryo Utakata1, Hisakazu Kato2
1Department of Otolaryngology - Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, JPN.
Abstract:
Malignant melanoma of the nasal cavity and paranasal sinuses is an extremely rare disease, with only a few reported cases originating from or extending into the nasolacrimal duct. Multimodal treatments, including surgery, radiotherapy, chemotherapy, immunotherapy, and immune checkpoint inhibitors, have been attempted; however, the treatment outcomes remain unsatisfactory. We herein report a case of primary malignant melanoma of the nasolacrimal duct, which was successfully managed through complete en bloc resection of the nasolacrimal duct along with the surrounding bony structures, lacrimal sac, and puncta, followed by adjuvant radiotherapy and administration of immune checkpoint inhibitors. This multidisciplinary approach resulted in a favorable clinical course. Due to the rarity of mucosal malignant melanoma, many aspects of the disease remain unclear, and further evidence is warranted.
Insights
Primary malignant melanoma of the nasolacrimal duct is rare. A multidisciplinary approach combining surgery, radiotherapy, and immune checkpoint inhibitors achieved a favorable outcome in one case.
Area of Science:
- Ophthalmology
- Oncology
- Head and Neck Surgery
Background:
- Malignant melanoma of the nasal cavity and paranasal sinuses is exceptionally rare.
- Cases involving the nasolacrimal duct are seldom reported.
- Existing multimodal treatments yield unsatisfactory outcomes.
More Related Videos
07:30Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
Published on: October 13, 2017
06:15Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024